453 related articles for article (PubMed ID: 31256905)
1. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
[TBL] [Abstract][Full Text] [Related]
2. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
Oriot P; Jérémie W; Buysschaert M
Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
[TBL] [Abstract][Full Text] [Related]
4. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
[TBL] [Abstract][Full Text] [Related]
5. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
6. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
Laubner K; Molz K; Kerner W; Karges W; Lang W; Dapp A; Schütt M; Best F; Seufert J; Holl RW
Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
[TBL] [Abstract][Full Text] [Related]
7. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
Wei W; Zhou S; Miao R; Pan C; Xie L; Baser O; Gill J
Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
[TBL] [Abstract][Full Text] [Related]
8. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
9. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
[TBL] [Abstract][Full Text] [Related]
10. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.
Porcellati F; Lin J; Lucidi P; Bolli GB; Fanelli CG
Medicine (Baltimore); 2017 Feb; 96(5):e6022. PubMed ID: 28151905
[TBL] [Abstract][Full Text] [Related]
11. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
Owens DR; Traylor L; Mullins P; Landgraf W
Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
[TBL] [Abstract][Full Text] [Related]
12. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.
Hong EG; Min KW; Lim JS; Ahn KJ; Ahn CW; Yu JM; Kim HS; Kim HJ; Kim W; Kim DH; Jang HC
Adv Ther; 2024 May; 41(5):1967-1982. PubMed ID: 38512540
[TBL] [Abstract][Full Text] [Related]
13. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
14. Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials.
Polonsky W; Traylor L; Gao L; Wei W; Ameer B; Stuhr A; Vlajnic A
J Diabetes Complications; 2017 Mar; 31(3):562-568. PubMed ID: 28040350
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.
Nakanishi S; Iwamoto M; Kamei S; Hirukawa H; Shimoda M; Tatsumi F; Kohara K; Obata A; Kimura T; Kinoshita T; Irie S; Sanada J; Fushimi Y; Nishioka M; Mizoguchi A; Kameyama M; Mune T; Kaku K; Kaneto H
Intern Med; 2018; 57(10):1381-1389. PubMed ID: 29760318
[TBL] [Abstract][Full Text] [Related]
16. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
17. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis.
Joshi SR; Singh G; Marwah A; Mittra S; Suvarna VR; Athalye SN
Diabetes Obes Metab; 2023 Jun; 25(6):1589-1606. PubMed ID: 36748186
[TBL] [Abstract][Full Text] [Related]
18. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.
Xie L; Wei W; Pan C; Du J; Baser O
Adv Ther; 2011 Nov; 28(11):1000-11. PubMed ID: 22038703
[TBL] [Abstract][Full Text] [Related]
19. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
[TBL] [Abstract][Full Text] [Related]
20. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
Bailey TS; Wu J; Zhou FL; Gupta RA; Menon AA; Berhanu P; Westerbacka J; Van Vleet J; Blonde L
Diabetes Obes Metab; 2019 Nov; 21(11):2384-2393. PubMed ID: 31264346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]